Charles Schwab’s Surgalign Holdings, Inc. Common Stock SRGA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,379
Closed -$30K 3653
2021
Q4
$30K Hold
1,379
﹤0.01% 3549
2021
Q3
$46K Hold
1,379
﹤0.01% 3463
2021
Q2
$58K Sell
1,379
-7,055
-84% -$361K ﹤0.01% 3349
2021
Q1
$552K Buy
8,434
+3,747
+80% +$261K ﹤0.01% 3040
2020
Q4
$308K Hold
4,687
﹤0.01% 3153
2020
Q3
$255K Sell
4,687
-172
-4% -$13.2K ﹤0.01% 3096
2020
Q2
$464K Buy
4,859
+260
+6% +$19.4K ﹤0.01% 2864
2020
Q1
$236K Buy
4,599
+31
+0.7% +$3.24K ﹤0.01% 2968
2019
Q4
$376K Hold
4,568
﹤0.01% 2923
2019
Q3
$391K Hold
4,568
﹤0.01% 2895
2019
Q2
$583K Buy
4,568
+186
+4% +$26.8K ﹤0.01% 2743
2019
Q1
$790K Buy
4,382
+185
+4% +$26.8K ﹤0.01% 2622
2018
Q4
$466K Hold
4,197
﹤0.01% 2798
2018
Q3
$567K Hold
4,197
﹤0.01% 2794
2018
Q2
$580K Buy
4,197
+587
+16% +$80.8K ﹤0.01% 2762
2018
Q1
$499K Hold
3,610
﹤0.01% 2731
2017
Q4
$445K Buy
3,610
+500
+16% +$68.7K ﹤0.01% 2751
2017
Q3
$425K Hold
3,110
﹤0.01% 2766
2017
Q2
$546K Sell
3,110
-2,766
-47% -$393K ﹤0.01% 2660
2017
Q1
$706K Hold
5,876
﹤0.01% 2535
2016
Q4
$573K Sell
5,876
-1,611
-22% -$148K ﹤0.01% 2605
2016
Q3
$703K Hold
7,487
﹤0.01% 2504
2016
Q2
$807K Buy
7,487
+1,200
+19% +$141K ﹤0.01% 2415
2016
Q1
$755K Buy
6,287
+1,733
+38% +$182K ﹤0.01% 2434
2015
Q4
$543K Hold
4,554
﹤0.01% 2611
2015
Q3
$777K Hold
4,554
﹤0.01% 2465
2015
Q2
$883K Buy
4,554
+1,487
+48% +$276K ﹤0.01% 2470
2015
Q1
$455K Hold
3,067
﹤0.01% 2659
2014
Q4
$479K Hold
3,067
﹤0.01% 2638
2014
Q3
$440K Hold
3,067
﹤0.01% 2632
2014
Q2
$401K Hold
3,067
﹤0.01% 2725
2014
Q1
$376K Sell
3,067
-2,943
-49% -$319K ﹤0.01% 2710
2013
Q4
$639K Sell
6,010
-1,417
-19% -$137K ﹤0.01% 2481
2013
Q3
$836K Sell
7,427
-1,139
-13% -$129K ﹤0.01% 2301
2013
Q2
$982K Buy
+8,566
New +$1.05M ﹤0.01% 2172

Other funds holding SRGA

Charles Schwab's SRGA Position: Q1 2022 in Review

Charles Schwab sold out of Surgalign Holdings, Inc. Common Stock (SRGA) in Q1 2022, closing a stake of 1,379 shares — an estimated $30K sold.

Charles Schwab first reported a position in SRGA in Q2 2013 and held it in 35 quarters. The position peaked at $982K in Q2 2013. 77 funds tracked by Wall St. Rank hold SRGA as of Q1 2022.

  • Charles Schwab reported no remaining Surgalign Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 1,379 Surgalign Holdings, Inc. Common Stock shares in Q1 2022, an estimated $30K.
  • Charles Schwab first reported a position in Surgalign Holdings, Inc. Common Stock in Q2 2013 and held it in 35 quarters.
  • Charles Schwab's Surgalign Holdings, Inc. Common Stock position peaked at $982K in Q2 2013.
  • 77 funds tracked by Wall St. Rank held Surgalign Holdings, Inc. Common Stock as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.